CENTRAL LABORATORIES WHITE PAPERS & ARTICLES

• Managing Opportunities And Risks In Generative AI Use For Clinical Research

  Explore how to bridge the gap between generative AI potential and clinical regulations through smarter oversight, adversarial agents, and a workforce prepared for human-AI collaboration.

• Futureproofing Post-Approval Compliance

  In the post-approval stage, a synergistic operating model brings PV and regulatory functions under one umbrella: a single governance structure with shared decision cycles, templates, and evidence.

• Improving Rare Disease Recruitment With Data And AI

  Finding patients for rare disease clinical trials can be an uphill battle; fortunately, there are ways sponsors can address the most common stumbling blocks in the recruitment process.

• How Sponsors Can Ensure Their Sites Are Aligned With ICH E6 R3

  Updated GCP expectations reshape sponsor–site collaboration. Clear guidance on systems, data governance, and monitoring reduces risk, strengthens oversight, and supports compliance with ICH E6(R3).

• Using AI To Close Critical Clinical Trial Gaps

  Clinical trials face rising data and protocol complexity, driving delays and failures. Using intelligence-driven planning helps predict feasibility, flag enrollment risks early, and build more resilient studies.